Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 -- Financing Led by Pivotal bioVenture Partners -- Company Announces Lead Product Candidate for the Prevention of a Potentially Life-Threatening Rare Disease that Impacts Fetuses and Newborns -- Portfolio Expansion Planned for 2020 NEW HAVEN, Conn., May 19, 2020-- Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the completion of a $145 million Series B financing led by Pivotal bioVenture Partners.